$Eli Lilly(LLY.US), $WUXI BIO(02269.HK), $WUXI APPTEC(02359.HK), $Hims & Hers Health(HIMS.US) were all basically flat, $Pfizer(PFE.US) dipped slightly, $SPDR S&P Biotech(XBI.US) rose a bit—this batch of pharma stocks was overall quiet.
The large caps didn't make any preemptive moves ahead of the earnings and healthcare policy window, CXO followed the pace of overseas orders, and small-cap biotechs lacking catalysts could only wait for data readouts🤔
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
